For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Decision to fund bedaquiline and linezolid for multi-drug resistant tuberculosis
This item is over 2 years old; some content may no longer be current
+Undoctored
Decision to fund bedaquiline and linezolid for multi-drug resistant tuberculosis
Tuesday 13 June 2023, 01:29 PM

Pharmac will fund bedaquiline and linezolid for multi-drug resistant tuberculosis (MDR-TB) from 1 July 2023
We're pleased to announce that from 1 July 2023 bedaquiline and linezolid will be funded for multi-drug resistant tuberculosis (MDR-TB) for both community and hospital use. This change will enable people with MDR-TB to be treated in the community where appropriate.